Designing Around Formulation Patents: The Generic Developers Playbook (and Why Its Getting Harder)
In generic drug development, the real fight often isnt about whether you can make a moleculeits about how you can make it.
Formulation patentscovering ev…

Pharma forensics is having a momentand its not just for patent attorneys.
In an industry where timelines are everything, the real competitive advantage often isnt the molecule. Its the lifecycle strategy: how a company extends exclusivity, reshapes mar…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the first battle is obvious: challenge the primary patent. But the second battlethe one that quietly determines timelines, costs, …

Patent cliff or patent opportunity? Mapping blockbuster expirations for strategic supply-chain readiness
The market loves a clean narrative: patent cliff = chaos, price collapse, and operational whiplash.
But the reality for pharma supply chains is m…

AI is getting better at finding whats not there. Thats a big deal for pharma IP.
In patent litigation and prosecution, the hardest prior art isnt always the obvious stuff. Its the hidden stuffthe references buried in long chemical descriptions, the alm…

Pharmas next IP chess move isnt always invent around the molecule. Its often design around the formulation.
If youre building a pipeline in a world of crowded patents, you already know the headline risk: competitors dont just block active ingredientsth…

Formulation Forensics: How to Read Excipient and Process Clues in Drug Patent Claims
Most people read drug patents like theyre legal documents. Investors, competitors, and serious R&D teams read them like theyre mapsbecause the real story is often …

The biosimilar patent dance isnt a formalityits the first move in a multi-year chess match.
If youre a biologics innovator or a biosimilar applicant, you already know the headlines: the dance is procedural, the stakes are commercial, and the litigation…

Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, 180-day exclusivity is often described like a prize at the end of a race. But the real story is less about luck and more about execution: timing, litigation strateg…

The Patent Dance Is No Longer a ChoreographyIts a Strategy War. Heres the Playbook.
If youve been anywhere near biologics and biosimilars over the last few years, you already know the script: the patent dance under the BPCIA is supposed to bring clarit…